CDKAL1 and Prostate Cancer
Principal Investigator
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
2007-0037
Initial CDAS Request Approval
Jun 12, 2007
Title
CDKAL1 and Prostate Cancer
Summary
CDKAL1 genotypes have been associated with Type 2 diabetes, with inter-relationships also with body mass index. The gene variants operate on insulin secretion (Steinthorsdottir, Nature Gen, online, 2007). Prostate cancer risk is related to a history of Type 2 diabetes (Kasper, CEBP, 2006). CGEMS whole genome scan shows several SNPs in the CDKAL1 gene region associated with prostate cancer in the PLCO Trial (strongest p x 10-5). With CGEMS genotype result for the SNPs in the CDKAL1 region and covariate data from the questionnaire and biochemical results, we plan to model the relationship of gene variants in CDKAL1, BMI, and diabetes with prostate cancer risk.
Aims
The primary focus of the analysis is on whether genes explain the observed association of phenotypes with cancer; that is, with gene in the model, does phenotype provide added information as a main effect of disease. Initial results will come from the PLCO Trial, which is suitably powered for this analysis. Follow-up will be through the cohorts of the BPC3 cohort consortium, which will allow for exploration of statistical interaction of genes x phenotype with disease. Results will be important to understand if anthropometric and diabetes associations with prostate cancer are at least in part explained by underlying genetics of CDKAL1.
Collaborators
Jiyoung Ahn
Sonja Berndt
Stephen Chanock
Wen-Yi Huang